ARTICLE | Company News
Lanthio Pharma, Tarix deal
February 20, 2012 8:00 AM UTC
Lanthio granted Tarix exclusive, worldwide rights to its lanthionine-Ang(1-7) peptide. According to Lanthio, the preclinical product targets the MAS receptor and is being developed for acute lung injury and related indications. Lanthio is eligible for milestones and royalties while Tarix will be responsible for funding further development. Details were not disclosed. ...